

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10566796	
	Filing Date		2006-01-31	
	First Named Inventor		Sweeney et al.	
	Art Unit		None	
	Examiner Name		Not Assigned	
	Attorney Docket Number		PENN0870US.NP	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	CA1219764			1987-03-31	Ho et al.		<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
--------------------	---------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number	10566796
		Filing Date	2006-01-31
		First Named Inventor	Sweeney et al.
		Art Unit	None
		Examiner Name	Not Assigned
		Attorney Docket Number	PENN0870US.NP

	1	Allen et al., "Apoptosis: a mechanism contributing to remodeling of skeletal muscle in response to hindlimb unweighting", Am. J. Physiol. 1997 273 (Cell Physiol. 42): C579-C587	<input checked="" type="checkbox"/>
	2	Allen et al., "Myonuclear Domains in Muscle Adaptation and Disease", 1999 Muscle Nerve 22: 1350-1360	<input checked="" type="checkbox"/>
	3	Badalamente et al., "Delay of Muscle Degeneration and Necrosis in mdx Mice by Calpain Inhibition", 2000 Muscle Nerve 23: 106-111	<input checked="" type="checkbox"/>
	4	Barton-Davis et al., "Viral Mediated Expression of Insulin-Like Growth Factor I Blocks the Aging-Related Loss of Skeletal Muscle Function", Proc. Natl Acad Sci USA Vol. 95, No. 26. December 22, 1998, pp. 15603-1560	<input checked="" type="checkbox"/>
	5	Billings et al., "Distribution of the Bowman Birk protease inhibitor in mice following oral administration", 1992, Cancer Letters 62 191-197	<input checked="" type="checkbox"/>
	6	Birk et al., "The Bowman-Birk inhibitor", Int. J. Peptide Protein Res. 25, 1985, 113-13	<input checked="" type="checkbox"/>
	7	Bodine et al., "Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo", Nature Cell Biology, vol. 3, November 2001, pp. 1014-1019	<input checked="" type="checkbox"/>
	8	Buetler et al., "Green Tea Extract Decreases Muscle Necrosis in mdx Mice and Protects Against Reactive Oxygen Species", Am. J. Clin. Nutr. 2002; 75:749-53	<input checked="" type="checkbox"/>
	9	Criswell et al., "Overexpression of IGF-I in skeletal muscle of transgenic mice does not prevent unloading-induced atrophy", Am. J. Physiol. 1998 275: E373-E379	<input checked="" type="checkbox"/>
	10	Goldberg et al., "Protein Turnover in Skeletal Muscle", The Journal of Biological Chemistry, Vol. 244, No. 12, 1969 pp. 3223-3229	<input checked="" type="checkbox"/>
	11	Gordon et al., "Plasticity in Skeletal, Cardiac, and Smooth Muscle Selected Contribution: Skeletal muscle focal adhesion kinase, paxillin, and serum response factor are loading dependent", J Appl Physiol 2001 90: 1174-1183	<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number	10566796
		Filing Date	2006-01-31
		First Named Inventor	Sweeney et al.
		Art Unit	None
		Examiner Name	Not Assigned
		Attorney Docket Number	PENN0870US.NP

	12	Granchelli et al., "Cromolyn Increases Strength in Exercised MDX Mice", Research Communications in Molecular Pathology and Pharmacology, Vol. 91, No. 3 March 1996 pp. 287-296	<input checked="" type="checkbox"/>
	13	Hornberger et al., "Regulation of translation factors during hindlimb unloading and denervation of skeletal muscle in rats", Am. J. Physiol. 2001 281:C179-C187	<input checked="" type="checkbox"/>
	14	Hunter et al., "Activation of an alternative NF- κ B pathway in skeletal muscle during disuse atrophy", The FASEB Journal, 2002 Vol. 16 pp. 529-538	<input checked="" type="checkbox"/>
	15	Ikemoto et al., "Space shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association with activation of ubiquitin-proteasome pathway", The FASEB Journal published online March 12, 2001	<input checked="" type="checkbox"/>
	16	Jaspers et al., "Atrophy and growth failure of rat hindlimb muscles in tail-cast suspension", The American Physiological Society, 1984 pp. 1472-1479	<input checked="" type="checkbox"/>
	17	Kennedy et al., "Preparation and Production of a Cancer Chemopreventative Agent, Bowman-Birk Inhibitor Concentrate", Nutr Cancer 1993 Vol. 19, No. 3, pp. 281-302	<input checked="" type="checkbox"/>
	18	Ann R. Kennedy, "Anticarcinogenic Activity of Protease Inhibitors", Protease Inhibitors as Cancer Chemopreventive Agents, edited by Walter Troll and Ann R. Kennedy. Plenum Press, New York, 1993	<input checked="" type="checkbox"/>
	19	Ann R. Kennedy, "Chemopreventative Agents: Protease Inhibitors", Pharmacol. Ther. Vol. 78, No. 3, pp. 167-209, 1998	<input checked="" type="checkbox"/>
	20	Larionova et al., "Inhibition of Cathepsin G and Human Granulocyte Elastase By Multiple Forms of Soybean Inhibitor of Bowman-Birk Type", Biokhimiya 1993 58:1437-1444	<input checked="" type="checkbox"/>
	21	Loughna et al., "Effect of Inactivity and Passive Stretch on Protein Turnover in Phasic and Postural Rat Muscles", J. Appl. Physiol. 1986 61(1) 173-179	<input checked="" type="checkbox"/>
	22	Mitchell et al., "A muscle Precursor Cell-Dependent Pathway Contributes to Muscle Growth After Atrophy", Am J Physiol Cell Physiol 281: C1706-C1715, 2001	<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10566796
	Filing Date	2006-01-31
	First Named Inventor	Sweeney et al.
	Art Unit	None
	Examiner Name	Not Assigned
	Attorney Docket Number	PENN0870US.NP

	23	Nikawa et al., "Effects of a Soy Protein Diet on Exercise-Induced Muscle Protein Catabolism in Rats", Nutrition 18:490-495, 2002	<input checked="" type="checkbox"/>
	24	Oreffo et al., "Actue effects of the Bowman-Birk protease inhibitor in mice", Toxicology, 69 (1991) 165-176	<input checked="" type="checkbox"/>
	25	Sangorrin et al., "Myofibril-bound Serine Protease and its Endogenous Inhibitor in Mouse: Extraction, Partial Characterization and Effect on Myofibrils", Comparative Biochemistry and Physiology Part B 131 (2002) 713-723	<input checked="" type="checkbox"/>
	26	Sawada et al., "Therapeutic Effect of Camostat Mesilate on Duchenne Muscular Dystrophy in mdx Mice", Pharmaceutical Society of Japan, 2003, Biol. Pharm. Bull. 26(7) 1025-1027	<input checked="" type="checkbox"/>
	27	Solomon et al., "Importance of the ATP-Ubiquitin-Proteasome Pathway in the Degradation of Soluble and Myofibrillar Proteins in Rabbit Muscle Extracts", The Journal of Biological Chemistry, 1996, Vol. 271, No. 43, 26690-26697	<input checked="" type="checkbox"/>
	28	Spencer et al., "Overexpression of Calpastatin Transgene in mdx Muscle Reduces Dystrophic Pathology", Human Molecular Genetics, 2002, Vol. 11, No. 21, pp. 2645-2655	<input checked="" type="checkbox"/>
	29	Stevenson et al., "Global Analysis of Gene Expression Patterns During Disuse Atrophy in Rat Skeletal Muscle", J. Physiol. 2003;551:33-48	<input checked="" type="checkbox"/>
	30	Tada et al., "Effect of Different Dietary Protein Composition on Skeletal Muscle Atrophy by Suspension Hypokinisia/Hypodynamia in Rats", J. Nutr. Sci. Vitaminol. 48. 115-119, 2002	<input checked="" type="checkbox"/>
	31	Taillardier et al., "Coordinate Activation of Lysosomal, Ca2+-Activated and ATP-ubiquitin-dependent Proteinases in the Unweighted Rat Soleus Muscle", Biochem. J. (1996) 316, 65-72	<input checked="" type="checkbox"/>
	32	Tawa et al., "Inhibitors of the Proteasome Reduce the Accelerated Proteolysis in Atrophying Rat Skeletal Muscles", J. Clin. Invest., Volume 100, Number 1, 997, pp. 197-203	<input checked="" type="checkbox"/>
	33	Tidball et al., "Expression of a Calpastatin Transgene Slows Muscle Wasting and Obviates Changes in Myosin Isoform Expression During Murine Muscle Disuse", J. Physiol. 2002;545:819-828	<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10566796
	Filing Date	2006-01-31
	First Named Inventor	Sweeney et al.
	Art Unit	None
	Examiner Name	Not Assigned
	Attorney Docket Number	PENN0870US.NP

	34	Tischler et al., "Different Mechanisms of Increased Proteolysis in Atrophy Induced by Denervation or Unweighting of Rat Soleus Muscle", Metabolism, Vol. 39, No. 7, 1990: pp. 756-763	<input checked="" type="checkbox"/>
	35	Ware et al., "Soybean Bowman-Birk Protease Inhibitor Is a Highly Effective Inhibitor of Human Mast Cell Chymase", Archives of Biochemistry and Biophysics, Vol. 344, No. 1, pp. 133-138, 1997	<input checked="" type="checkbox"/>
	36	Yavelow et al., "Nanomolar Concentrations of Bowman-Birk Soybean Protease Inhibitor Suppress x-ray-induced Transformation in Vitro", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 5395-5399, 1985	<input checked="" type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.</p>			

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10566796
Filing Date	2006-01-31
First Named Inventor	Sweeney et al.
Art Unit	None
Examiner Name	Not Assigned
Attorney Docket Number	PENN0870US.NP

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	//Kathleen A. Tyrrell//	Date (YYYY-MM-DD)	2007-04-17
Name/Print	Kathleen A. Tyrrell	Registration Number	38,350

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.